Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sana Biotechnology Inc (SANA)

Sana Biotechnology Inc (SANA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,046,818
  • Shares Outstanding, K 266,366
  • Annual Sales, $ 0 K
  • Annual Income, $ -266,760 K
  • EBIT $ -240 M
  • EBITDA $ -223 M
  • 60-Month Beta 1.96
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.25

Options Overview Details

View History
  • Implied Volatility 135.95% (+5.16%)
  • Historical Volatility 74.09%
  • IV Percentile 71%
  • IV Rank 14.22%
  • IV High 533.46% on 04/08/25
  • IV Low 70.03% on 01/27/26
  • Expected Move (DTE 29) 1.11 (26.69%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 835
  • Volume Avg (30-Day) 873
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 38,344
  • Open Int (30-Day) 36,414
  • Expected Range 3.04 to 5.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.12
  • Number of Estimates 5
  • High Estimate -0.09
  • Low Estimate -0.15
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +47.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.53 +17.28%
on 02/05/26
5.20 -20.38%
on 01/27/26
-0.44 (-9.61%)
since 01/16/26
3-Month
3.16 +31.01%
on 11/21/25
5.49 -24.59%
on 12/04/25
+0.74 (+21.76%)
since 11/19/25
52-Week
1.26 +228.57%
on 04/04/25
6.55 -36.79%
on 10/15/25
+1.05 (+33.98%)
since 02/19/25

Most Recent Stories

More News
Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer

SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of...

SANA : 4.14 (+5.34%)
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast...

SANA : 4.14 (+5.34%)
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in November...

ONCY : 1.0000 (-1.96%)
SANA : 4.14 (+5.34%)
ABSI : 2.78 (+2.96%)
RXRX : 3.72 (+5.38%)
TEM : 59.96 (+6.77%)
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology  Broadens Application...

SANA : 4.14 (+5.34%)
Sana Biotechnology to Present at December 2025 Investor Conferences

SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast...

SANA : 4.14 (+5.34%)
Sana: Q3 Earnings Snapshot

Sana: Q3 Earnings Snapshot

SANA : 4.14 (+5.34%)
Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates

Announced increased focus on type 1 diabetes and in vivo CAR T programs Regulatory interactions increase confidence in moving forward with GMP master cell bank for SC451, nonclinical testing plan,...

SANA : 4.14 (+5.34%)
Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit

SEATTLE, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast...

SANA : 4.14 (+5.34%)
3 Stocks to Buy Under $10 That Could Triple From Here

Not all great investment opportunities are expensive.

IOVA : 2.85 (+4.78%)
BCYC : 5.54 (+2.97%)
SANA : 4.14 (+5.34%)
Sana Biotechnology to Present at September 2025 Investor Conferences

SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast...

SANA : 4.14 (+5.34%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

Sana Biotechnology Inc. is focused on creating and delivering engineered cells as medicines for patients. The company involved in repairing and controlling genes, replacing missing or damaged cells as well as making its therapies. Sana Biotechnology Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 4.63
2nd Resistance Point 4.41
1st Resistance Point 4.27
Last Price 4.14
1st Support Level 3.91
2nd Support Level 3.69
3rd Support Level 3.55

See More

52-Week High 6.55
Fibonacci 61.8% 4.53
Last Price 4.14
Fibonacci 50% 3.91
Fibonacci 38.2% 3.28
52-Week Low 1.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar